To include your compound in the COVID-19 Resource Center, submit it here.

J&J's Erleada meets in Phase III for non-metastatic CRPC

Johnson & Johnson (NYSE:JNJ) said Erleada apalutamide (JNJ56021927) met the primary endpoint in the Phase III SPARTAN trial to treat non-metastatic castration-resistant prostate cancer (CRPC). Data were presented

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE